Pharmaceutical companies are in the hot seat for allegedly pushing drugs for uses not approved by the government, a growing practice that has triggered a congressional investigation, litigation and hefty settlements.

Attorneys and legal experts say that scores of private and government lawsuits have been filed in the past two years, charging drug companies with illegally influencing doctors to prescribe drugs for unapproved uses — a practice known as “off-labeling.”

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]